Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 85026
1. Gustafsson M, Sjölander M, Pfister B, Jonsson J, Schneede J, Lövheim H: Pharmacist participation in hospital ward teams and hospital readmission rates among people with dementia: a randomized controlled trial. Eur J Clin Pharmacol; 2017 Jul;73(7):827-835

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacist participation in hospital ward teams and hospital readmission rates among people with dementia: a randomized controlled trial.
  • PURPOSE: To assess whether comprehensive medication reviews conducted by clinical pharmacists as part of a healthcare team reduce drug-related hospital readmission rates among people with dementia or cognitive impairment.
  • Patients aged ≥65 years with dementia or cognitive impairment admitted to three wards at two hospitals located in Northern Sweden were included.
  • The primary outcome, risk of drug-related hospital readmissions, was assessed at 180 days of follow-up by intention-to-treat analysis.
  • CONCLUSION: Participation of clinical pharmacists in healthcare team conducting comprehensive medication reviews did not significantly reduce the risk of drug-related readmissions in patients with dementia or cognitive impairment; however, post-hoc and subgroup analyses indicated significant effects favoring the intervention.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharm World Sci. 2006 Jun;28(3):152-8 [17004023.001]
  • [Cites] Am J Geriatr Pharmacother. 2003 Dec;1(2):82-9 [15555470.001]
  • [Cites] J Eval Clin Pract. 2007 Oct;13(5):781-8 [17824872.001]
  • [Cites] Ann Pharmacother. 2002 Jul-Aug;36(7-8):1238-48 [12086559.001]
  • [Cites] Res Social Adm Pharm. 2014 Jul-Aug;10(4):608-22 [24161491.001]
  • [Cites] Clin Drug Investig. 2010;30(5):289-300 [20384385.001]
  • [Cites] Cochrane Database Syst Rev. 2013 Feb 28;(2):CD008986 [23450593.001]
  • [Cites] Arch Intern Med. 2009 May 11;169(9):894-900 [19433702.001]
  • [Cites] Arch Intern Med. 2008 Apr 14;168(7):687-94 [18413550.001]
  • [Cites] Med Care. 2010 Oct;48(10):923-33 [20720510.001]
  • [Cites] Cochrane Database Syst Rev. 2010 Jul 07;(7):CD000336 [20614422.001]
  • [Cites] Am J Geriatr Psychiatry. 2008 Jul;16(7):528-36 [18591573.001]
  • [Cites] Neurol Sci. 2009 Apr;30(2):87-92 [19229475.001]
  • [Cites] JAMA Intern Med. 2015 Nov;175(11):1803-12 [26368317.001]
  • [Cites] BMC Pharmacol Toxicol. 2013 Feb 08;14:10 [23391323.001]
  • [Cites] Arch Intern Med. 2005 Jan 10;165(1):68-74 [15642877.001]
  • [Cites] Eur J Clin Pharmacol. 2016 Sep;72 (9):1143-53 [27377393.001]
  • [Cites] JAMA. 2015 Oct 27;314(16):1681-2 [26505584.001]
  • [Cites] J Patient Saf. 2015 Mar 4;:null [25742062.001]
  • [Cites] Arch Intern Med. 1990 Apr;150(4):841-5 [2327844.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2013 Jun;112(6):359-73 [23506448.001]
  • [Cites] JAMA. 1998 Apr 15;279(15):1200-5 [9555760.001]
  • [Cites] PLoS One. 2014 Nov 07;9(11):e112282 [25379675.001]
  • [Cites] J Manag Care Pharm. 2013 Jun;19(5):408-16 [23697478.001]
  • [Cites] Lancet. 2007 Jul 14;370(9582):173-84 [17630041.001]
  • [Cites] Eur Heart J. 2006 Feb;27(4):434-40 [16230302.001]
  • [Cites] J Am Geriatr Soc. 2010 Apr;58(4):627-35 [20398146.001]
  • [Cites] Intern Med J. 2001 May-Jun;31(4):199-205 [11456032.001]
  • (PMID = 28391409.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Clinical pharmacists / Dementia / Drug-related readmissions / Medication reviews / Old people
  •  go-up   go-down


2. Sommer I, Griebler U, Kien C, Auer S, Klerings I, Hammer R, Holzer P, Gartlehner G: Vitamin D deficiency as a risk factor for dementia: a systematic review and meta-analysis. BMC Geriatr; 2017 Jan 13;17(1):16
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin D deficiency as a risk factor for dementia: a systematic review and meta-analysis.
  • BACKGROUND: Sunlight exposure and high vitamin D status have been hypothesised to reduce the risk of developing dementia.
  • The objective of our research was to determine whether lack of sunlight and hypovitaminosis D over time are associated with dementia.
  • We conducted random effects meta-analyses of published and unpublished data to evaluate the influence of sunlight exposure or vitamin D as a surrogate marker on dementia risk.
  • RESULTS: We could not identify a single study investigating the association between sunlight exposure and dementia risk.
  • Six cohort studies provided data on the effect of serum vitamin D concentration on dementia risk.
  • The strength of evidence that serious vitamin D deficiency increases the risk of developing dementia, however, is very low due to the observational nature of included studies and their lack of adjustment for residual or important confounders (e.g.
  • ApoE ε4 genotype), as well as the indirect relationship between Vitamin D concentrations as a surrogate for sunlight exposure and dementia risk.
  • CONCLUSIONS: The results of this systematic review show that low vitamin D levels might contribute to the development of dementia.
  • Further research examining the direct and indirect relationship between sunlight exposure and dementia risk is needed.
  • Such research should involve large-scale cohort studies with homogeneous and repeated assessment of vitamin D concentrations or sunlight exposure and dementia outcomes.
  • [MeSH-major] Dementia / blood. Dementia / psychology. Sunlight. Vitamin D Deficiency / blood. Vitamin D Deficiency / psychology

  • MedlinePlus Health Information. consumer health - Dementia.
  • MedlinePlus Health Information. consumer health - Vitamin D Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2007 Jul 19;357(3):266-81 [17634462.001]
  • [Cites] Nutr Bull. 2014 Dec;39(4):322-350 [25635171.001]
  • [Cites] J Clin Epidemiol. 2011 Dec;64(12):1277-82 [21802904.001]
  • [Cites] J Alzheimers Dis. 2013;33(3):659-74 [23042216.001]
  • [Cites] Ann N Y Acad Sci. 2016 Mar;1367(1):57-63 [27116242.001]
  • [Cites] Neurology. 2012 Sep 25;79(13):1397-405 [23008220.001]
  • [Cites] Syst Rev. 2015 Jan 01;4:1 [25554246.001]
  • [Cites] J Clin Epidemiol. 2011 Apr;64(4):407-15 [21247734.001]
  • [Cites] Front Mol Neurosci. 2015 Oct 07;8:58 [26468295.001]
  • [Cites] J Clin Epidemiol. 2010 May;63(5):474-5 [20189352.001]
  • [Cites] J Alzheimers Dis. 2014;42 Suppl 3:S53-61 [24898645.001]
  • [Cites] Eur J Neurol. 2014 Sep;21(9):1211-8, e69-70 [24846449.001]
  • [Cites] Epidemiology. 2014 Nov;25(6):799-804 [25215530.001]
  • [Cites] Neurology. 2014 Sep 2;83(10):920-8 [25098535.001]
  • [Cites] Eur J Clin Nutr. 2013 Mar;67(3):270-4 [23388663.001]
  • [Cites] PLoS One. 2013 Jun 21;8(6):e65785 [23805188.001]
  • [Cites] J Clin Epidemiol. 2011 Dec;64(12):1294-302 [21803546.001]
  • [Cites] J Clin Epidemiol. 2011 Dec;64(12):1311-6 [21802902.001]
  • [Cites] Lancet Neurol. 2016 Jan;15(1):116-24 [26300044.001]
  • [Cites] J Clin Epidemiol. 2011 Dec;64(12):1283-93 [21839614.001]
  • [Cites] J Chem Neuroanat. 2005 Jan;29(1):21-30 [15589699.001]
  • [Cites] J Cereb Blood Flow Metab. 2016 Jan;36(1):172-86 [26174330.001]
  • [Cites] Stroke. 2006 Feb;37(2):345-50 [16397184.001]
  • [Cites] Osteoporos Int. 2009 Nov;20(11):1807-20 [19543765.001]
  • [Cites] Clin Chem. 2012 Mar;58(3):531-42 [22230812.001]
  • [Cites] Alzheimers Dement. 2014 May;10(3):296-302 [23871764.001]
  • [Cites] Dement Geriatr Cogn Disord. 2011;32(4):273-8 [22261995.001]
  • [Cites] Am J Epidemiol. 2010 Apr 15;171(8):903-8 [20219763.001]
  • [Cites] J Bone Miner Res. 2012 Jun;27(6):1381-9 [22407786.001]
  • [Cites] Evid Rep Technol Assess (Full Rep). 2010 Apr;(193):1-727 [21500874.001]
  • [Cites] J Clin Epidemiol. 2011 Apr;64(4):401-6 [21208779.001]
  • [Cites] Am J Geriatr Pharmacother. 2010 Feb;8(1):4-33 [20226390.001]
  • [Cites] J Clin Epidemiol. 2011 Dec;64(12):1303-10 [21802903.001]
  • [Cites] Lancet Neurol. 2016 Apr;15(5):455-532 [26987701.001]
  • (PMID = 28086755.001).
  • [ISSN] 1471-2318
  • [Journal-full-title] BMC geriatrics
  • [ISO-abbreviation] BMC Geriatr
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Keywords] NOTNLM ; Dementia / Meta-analysis / Systematic review / Vitamin D
  •  go-up   go-down


3. Tsiachristas A, Smith AD: B-vitamins are potentially a cost-effective population health strategy to tackle dementia: Too good to be true? Alzheimers Dement (N Y); 2016 Sep;2(3):156-161

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-vitamins are potentially a cost-effective population health strategy to tackle dementia: Too good to be true?
  • INTRODUCTION: To respond to the threat of dementia to public health and the economy, we need to prioritize research resources on strategies that would be the most effective.
  • In relation to the prevention of dementia, this article considers whether lowering plasma homocysteine by B-vitamin supplementation is one of the top priority and cost-effective treatments.
  • DISCUSSION: We anticipate that this provocative finding will be debated by scientists, clinicians, and policy makers and eventually be tested in future clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Health Technol Assess. 2001;5(1):1-137 [11262420.001]
  • [Cites] J Alzheimers Dis. 2011;26(4):735-44 [21709377.001]
  • [Cites] BMJ Open. 2015 Apr 13;5(4):e006648 [25869683.001]
  • [Cites] Int J Geriatr Psychiatry. 2010 Jan;25(1):82-90 [19484711.001]
  • [Cites] JAMA. 2008 Oct 15;300(15):1774-83 [18854539.001]
  • [Cites] Clin Chem. 2008 May;54(5):801-13 [18375482.001]
  • [Cites] Am J Psychiatry. 2007 Jun;164(6):861-7 [17541043.001]
  • [Cites] BMC Public Health. 2014 Jun 24;14:643 [24962204.001]
  • [Cites] Sci Rep. 2015 Jul 21;5:10585 [26194346.001]
  • [Cites] Prev Med. 2016 Apr;85:78-83 [26825761.001]
  • [Cites] Alzheimers Dement. 2013 Jan;9(1):58-62 [23141385.001]
  • [Cites] PLoS One. 2010 Sep 08;5(9):e12244 [20838622.001]
  • [Cites] J Intern Med. 2014 Mar;275(3):304-16 [24605810.001]
  • [Cites] Int J Geriatr Psychiatry. 2009 Jul;24(7):748-54 [19206079.001]
  • [Cites] JAMA. 2015 Apr 7;313(13):1325-35 [25771069.001]
  • [Cites] Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9523-8 [23690582.001]
  • [Cites] Int J Geriatr Psychiatry. 2012 Jun;27(6):592-600 [21780182.001]
  • [Cites] Curr Alzheimer Res. 2010 Jun;7(4):358-67 [19939223.001]
  • [Cites] Clinicoecon Outcomes Res. 2011;3:189-95 [22046104.001]
  • [Cites] Annu Rev Nutr. 2016 Jul 17;36:211-39 [27431367.001]
  • [Cites] Lancet Neurol. 2016 Apr;15(5):455-532 [26987701.001]
  • [Cites] Clin Chem. 2004 Jan;50(1):3-32 [14709635.001]
  • [Cites] Lancet. 2007 Jan 20;369(9557):208-16 [17240287.001]
  • [Cites] J Alzheimers Dis. 2014;38(4):699-703 [24326609.001]
  • [Cites] Value Health. 2011 Jul-Aug;14(5):621-30 [21839398.001]
  • (PMID = 29067302.001).
  • [ISSN] 2352-8737
  • [Journal-full-title] Alzheimer's & dementia (New York, N. Y.)
  • [ISO-abbreviation] Alzheimers Dement (N Y)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; B-Vitamins / Cost-effectiveness / Dementia / Homocysteine / UK
  •  go-up   go-down


Advertisement
4. Kenawy S, Hegazy R, Hassan A, El-Shenawy S, Gomaa N, Zaki H, Attia A: Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin. PLoS One; 2017;12(8):e0183565
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin.
  • Age-related dementia is one of the most devastating disorders affecting the elderly.
  • Recently, emerging data suggest that impaired insulin signaling is the major contributor in the development of Alzheimer's dementia (AD), which is the most common type of senile dementia.
  • Reversing of these harmful effects by the use of insulin-sensitizing drugs like Met and Saxa suggests their involvement in alleviation insulin resistance as the underlying pathology of AD and hence their potential use as anti-dementia drugs.
  • [MeSH-major] Adamantane / analogs & derivatives. Aging / pathology. Dementia / chemically induced. Dipeptides / toxicity. Galactose / toxicity. Hypoglycemic Agents / therapeutic use. Insulin Resistance. Metformin / therapeutic use

  • MedlinePlus Health Information. consumer health - Dementia.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. METFORMIN HYDROCHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gerontologist. 2016 Apr;56 Suppl 2:S167-77 [26994258.001]
  • [Cites] Oxid Med Cell Longev. 2014;2014:320513 [24669284.001]
  • [Cites] Nat Med. 2004 Jul;10(7):719-26 [15195085.001]
  • [Cites] J Lab Clin Med. 1963 May;61:882-8 [13967893.001]
  • [Cites] J Alzheimers Dis. 2016;51(4):1197-208 [26967226.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2004 Mar;286(3):R431-44 [14761864.001]
  • [Cites] J Neurogenet. 2015;29(2-3):50-8 [26119401.001]
  • [Cites] Cold Spring Harb Perspect Med. 2016 Mar 01;6(3):a025932 [26931809.001]
  • [Cites] Neurobiol Learn Mem. 2011 Oct;96(3):432-42 [21907815.001]
  • [Cites] Mol Psychiatry. 2003 Sep;8(9):786-96 [12931206.001]
  • [Cites] Mol Neurobiol. 2017 Jan;54(1):255-271 [26738855.001]
  • [Cites] J Neurol Sci. 2006 Jun 15;245(1-2):21-33 [16631207.001]
  • [Cites] Mol Psychiatry. 2010 Nov;15(11):1046-52 [20966918.001]
  • [Cites] Vascul Pharmacol. 2016 Jan;76:62-71 [26455387.001]
  • [Cites] Neuropharmacology. 2016 Feb;101:123-36 [26211973.001]
  • [Cites] J Diabetes Complications. 2016 May-Jun;30(4):746-52 [26796432.001]
  • [Cites] J Ethnopharmacol. 2016 Feb 17;179:162-9 [26721223.001]
  • [Cites] Kidney Res Clin Pract. 2016 Jun;35(2):69-77 [27366660.001]
  • [Cites] Gerontologist. 1997 Apr;37(2):150-6 [9127971.001]
  • [Cites] CNS Neurol Disord Drug Targets. 2016;15(3):329-36 [26831258.001]
  • [Cites] Pharmacol Biochem Behav. 2012 Jun;101(4):564-74 [22425595.001]
  • [Cites] J Alzheimers Dis. 2005 Dec;8(3):247-68 [16340083.001]
  • [Cites] Curr Top Med Chem. 2016;16(5):485-92 [26268336.001]
  • [Cites] Behav Brain Res. 2011 Jun 20;220(1):30-41 [21262264.001]
  • [Cites] Expert Rev Neurother. 2010 May;10(5):683-91 [20420489.001]
  • [Cites] J Neurochem. 2004 Jun;89(6):1313-7 [15189333.001]
  • [Cites] Neuropharmacology. 2013 Sep;72:291-300 [23603201.001]
  • [Cites] Expert Opin Investig Drugs. 2015 Mar;24(3):393-9 [25586103.001]
  • [Cites] Curr Atheroscler Rep. 2016 Apr;18(4):16 [26888066.001]
  • [Cites] J Neuroimmunol. 1999 Jan 1;93(1-2):182-93 [10378882.001]
  • [Cites] Mol Neurobiol. 2016 Apr;53(3):1741-1752 [25744568.001]
  • [Cites] Anal Biochem. 1989 Aug 1;180(2):248-52 [2573290.001]
  • [Cites] Biotherapy. 1991;3(2):127-33 [2054253.001]
  • [Cites] Brain Res Bull. 2017 Jul;133:88-96 [27316747.001]
  • [Cites] Alzheimers Dement. 2016 Jun;12(6):719-32 [27179961.001]
  • [Cites] J Vis Exp. 2011 Jul 20;(53):null [21808223.001]
  • [Cites] Arch Neurol. 2011 Jan;68(1):51-7 [20837822.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Cell Cycle. 2014;13(6):898-909 [24552807.001]
  • [Cites] J Pharm Sci. 1983 May;72(5):465-92 [6345750.001]
  • [Cites] J Nutr Health Aging. 2016 Apr;20(4):439-45 [26999245.001]
  • [Cites] Eur J Pharmacol. 2011 Jun 25;660(2-3):363-7 [21497160.001]
  • [Cites] Rev Neurosci. 2011;22(3):285-94 [21568789.001]
  • [Cites] J Cell Sci. 2001 Apr;114(Pt 8):1429-30 [11282018.001]
  • [Cites] Ann N Y Acad Sci. 2008 Apr;1126:147-51 [18448809.001]
  • [Cites] Lancet. 1994 Sep 17;344(8925):769-72 [7916070.001]
  • [Cites] J Alzheimers Dis. 2016;51(2):515-23 [26890783.001]
  • [Cites] PLoS One. 2015 Dec 02;10(12):e0143814 [26629991.001]
  • [Cites] Biomed Rep. 2016 May;4(5):519-522 [27123241.001]
  • [Cites] Mol Neurobiol. 2013 Dec;48(3):556-70 [23546742.001]
  • (PMID = 28832656.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Dipeptides; 0 / Hemoglobin A, Glycosylated; 0 / Hypoglycemic Agents; 0 / Nerve Tissue Proteins; 9100L32L2N / Metformin; 9GB927LAJW / saxagliptin; PJY633525U / Adamantane; X2RN3Q8DNE / Galactose
  •  go-up   go-down


5. Friberg L, Rosenqvist M: Less dementia with oral anticoagulation in atrial fibrillation. Eur Heart J; 2017 Oct 24;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Less dementia with oral anticoagulation in atrial fibrillation.
  • Aims: The association between atrial fibrillation (AF) and dementia is well documented, but it is not clear if oral anticoagulant treatment offers protection.
  • The aim of the study is therefore to compare the incidence of new dementia in patients with AF with and without oral anticoagulants, and to explore if there is a difference between novel anticoagulants and warfarin in this respect.
  • Methods and results: Retrospective registry study of all patients with hospital diagnosis of AF and no previous diagnosis of dementia in Sweden between 2006 and 2014.
  • Patients on anticoagulant treatment at baseline was associated with 29% lower risk of dementia than patients without anticoagulant treatment [hazard ratio (HR) 0.71, 95% confidence intervals (95% CI) 0.68-0.74] and 48% lower risk analysed on treatment (HR 0.52, 95% CI 0.50-055).
  • Conclusion: The risk of dementia is higher without oral anticoagulant treatment in patients with AF.


6. Wang R, Chen Z, Fu Y, Wei X, Liao J, Liu X, He B, Xu Y, Zou J, Yang X, Weng R, Tan S, McElroy C, Jin K, Wang Q: Plasma Cystatin C and High-Density Lipoprotein Are Important Biomarkers of Alzheimer's Disease and Vascular Dementia: A Cross-Sectional Study. Front Aging Neurosci; 2017;9:26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma Cystatin C and High-Density Lipoprotein Are Important Biomarkers of Alzheimer's Disease and Vascular Dementia: A Cross-Sectional Study.
  • <b>Objectives</b>: Cystatin C (Cys C) and high-density lipoprotein (HDL) play critical roles in neurodegenerative diseases, such as dementia, Alzheimer's disease (AD) and vascular dementia (VaD).
  • However, whether they can be used as reliable biomarkers to distinguish patients with dementia from healthy subjects and to determine disease severity remain largely unknown.
  • <b>Methods</b>: We conducted a cross-sectional study to determine plasma Cys C and HDL levels of 88 patients with dementia (43 AD patients, 45 VaD patients) and 45 healthy age-matched controls.
  • The severity of dementia was determined based on the Schwab and England Activities of Daily Living (ADL) Scale, the Mini-mental State Examination (MMSE), the Global Deterioration Scale (GDS), the Lawton Instrumental ADL (IADL) Scale, and the Hachinski Ischemia Scale (Hachinski).
  • Receiver operating characteristic (ROC) curves were calculated to determine the diagnostic accuracy of Cys C and HDL levels in distinguishing patients with dementia from healthy subjects.
  • <b>Conclusions</b>: Our findings suggest that the inflammatory mediators Cys C and HDL may play important roles in the pathogenesis of dementia, and plasma Cys C and HDL levels may be useful screening tools for differentiating AD/VaD patients from healthy subjects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Front Aging Neurosci. 2015 Oct 27;7:203 [26578949.001]
  • [Cites] Curr Alzheimer Res. 2011 Mar;8(2):187-96 [21222606.001]
  • [Cites] J Alzheimers Dis. 2014;40(2):399-408 [24448787.001]
  • [Cites] Curr Alzheimer Res. 2014 May;11(4):340-8 [24720893.001]
  • [Cites] PLoS One. 2013;8(1):e55328 [23383156.001]
  • [Cites] Prog Neurobiol. 2013 Nov;110:2-28 [24036231.001]
  • [Cites] Neurology. 2008 Sep 30;71(14):1072-9 [18824671.001]
  • [Cites] Front Aging Neurosci. 2014 Jun 12;6:121 [24971061.001]
  • [Cites] Neurology. 1993 Feb;43(2):250-60 [8094895.001]
  • [Cites] Front Cell Neurosci. 2012 Dec 12;6:58 [23248582.001]
  • [Cites] Brain. 2011 Jan;134(Pt 1):258-77 [21186265.001]
  • [Cites] Front Cell Neurosci. 2014 Aug 14;8:231 [25177270.001]
  • [Cites] J Alzheimers Dis. 2010;21(2):471-8 [20555147.001]
  • [Cites] Cell Metab. 2014 Apr 1;19(4):574-91 [24508505.001]
  • [Cites] Neurology. 2014 Jul 1;83(1):40-7 [24907234.001]
  • [Cites] Front Mol Neurosci. 2012 Jul 06;5:79 [22783166.001]
  • [Cites] Front Aging Neurosci. 2016 Jul 28;8:179 [27516739.001]
  • [Cites] Neurobiol Aging. 2013 May;34(5):1389-96 [23273574.001]
  • [Cites] Front Aging Neurosci. 2010 Jul 15;2:null [20725527.001]
  • [Cites] J Alzheimers Dis. 2010;22(3):985-91 [20858959.001]
  • [Cites] J Neurochem. 2012 Aug;122(4):752-63 [22679891.001]
  • [Cites] Neurobiol Dis. 2014 Dec;72 Pt A:22-36 [25131449.001]
  • [Cites] Aging Dis. 2013 Mar 07;4(2):57-64 [23696950.001]
  • [Cites] Mol Neurodegener. 2015 Dec 01;10:64 [26627638.001]
  • [Cites] Mol Neurobiol. 2014 Apr;49(2):1043-54 [24203677.001]
  • [Cites] J Alzheimers Dis. 2009;16(2):389-97 [19221428.001]
  • [Cites] Front Cell Neurosci. 2015 Jul 06;9:247 [26217177.001]
  • [Cites] Front Biosci (Schol Ed). 2011 Jan 01;3:541-54 [21196395.001]
  • [Cites] Aging Dis. 2015 Oct 01;6(5):322-30 [26425387.001]
  • [Cites] PLoS One. 2013 Apr 23;8(4):e62354 [23626805.001]
  • [Cites] Neurology. 2014 Nov 11;83(20):1812-8 [25305153.001]
  • [Cites] Autophagy. 2011 Jul;7(7):788-9 [21464620.001]
  • [Cites] Sci Rep. 2016 Aug 04;6:30741 [27489174.001]
  • [Cites] Neurobiol Dis. 2005 Feb;18(1):152-65 [15649706.001]
  • [Cites] Am J Pathol. 2010 Nov;177(5):2256-67 [20889561.001]
  • [Cites] Front Aging Neurosci. 2013 Sep 09;5:50 [24058343.001]
  • [Cites] Nat Genet. 2007 Dec;39(12):1440-2 [18026100.001]
  • [Cites] Neurobiol Aging. 2011 Aug;32(8):1435-42 [19773092.001]
  • [Cites] Brain. 2014 Dec;137(Pt 12):3300-18 [25270989.001]
  • [Cites] Prog Neurobiol. 2015 Jul 21;:null [26209472.001]
  • [Cites] Neurology. 1984 Jul;34(7):939-44 [6610841.001]
  • (PMID = 28223934.001).
  • [ISSN] 1663-4365
  • [Journal-full-title] Frontiers in aging neuroscience
  • [ISO-abbreviation] Front Aging Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Alzheimer’s disease / cystatin C / dementia / high-density lipoprotein / vascular dementia
  •  go-up   go-down


7. Karlsson S, Rahm Hallberg I, Midlöv P, Fagerström C: Trends in treatment with antipsychotic medication in relation to national directives, in people with dementia - a review of the Swedish context. BMC Psychiatry; 2017 Jul 14;17(1):251
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in treatment with antipsychotic medication in relation to national directives, in people with dementia - a review of the Swedish context.
  • BACKGROUND: The aim of this study was to explore trends in treatment with antipsychotic medication in Swedish dementia care in nursing homes as reported in the most recent empirical studies on the topic, and to relate these trends to directives from the national authorities.
  • The scoping review showed that treatment with antipsychotic drugs varied between 6% and 38%, and was higher in younger older persons and in those with moderate cognitive impairment and living in nursing homes for people with dementia.
  • CONCLUSIONS: Directives from the authorities in Sweden may have had an impact on treatment with antipsychotic medication for people with dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Health Serv Res. 2012 Oct;47(5):1791-813 [22946859.001]
  • [Cites] J Am Geriatr Soc. 2002 Jun;50(6):995-1000 [12110057.001]
  • [Cites] Int Psychogeriatr. 2009 Oct;21(5):941-8 [19586566.001]
  • [Cites] Arch Intern Med. 2007 Apr 9;167(7):676-83 [17420426.001]
  • [Cites] Int Psychogeriatr. 2010 Nov;22(7):1154-60 [20478102.001]
  • [Cites] Am J Geriatr Psychiatry. 2015 Dec;23(12):1259-69 [26525997.001]
  • [Cites] Lancet. 2005 Dec 17;366(9503):2112-7 [16360788.001]
  • [Cites] Int J Surg. 2010;8(5):336-41 [20171303.001]
  • [Cites] Dement Geriatr Cogn Disord. 2008;26(5):458-66 [18984956.001]
  • [Cites] Int J Geriatr Psychiatry. 2013 Jul;28(7):700-9 [22887592.001]
  • [Cites] BMC Public Health. 2012 Jan 23;12:68 [22269343.001]
  • [Cites] Ann Pharmacother. 2012 Jul-Aug;46(7-8):917-28 [22811347.001]
  • [Cites] Clin Drug Investig. 2010;30(5):289-300 [20384385.001]
  • [Cites] Health Serv Res. 2011 Dec;46(6pt1):1698-719 [21790590.001]
  • [Cites] Health Technol Assess. 2014 Jun;18(39):1-226, v-vi [24947468.001]
  • [Cites] Dement Geriatr Cogn Disord. 2004;17(1-2):78-90 [14566100.001]
  • [Cites] Aust N Z J Psychiatry. 2013 Jan;47(1):74-87 [23144164.001]
  • [Cites] Eur Neuropsychopharmacol. 2014 Jan;24(1):95-104 [24126116.001]
  • [Cites] Aging Clin Exp Res. 2004 Apr;16(2):158-68 [15195992.001]
  • [Cites] Int J Geriatr Psychiatry. 2009 Dec;24(12):1386-95 [19370714.001]
  • [Cites] BMC Pharmacol Toxicol. 2013 Nov 07;14:56 [24196341.001]
  • [Cites] Int J Geriatr Psychiatry. 2008 Mar;23(3):289-94 [17645282.001]
  • [Cites] Health Econ. 2012 Aug;21(8):977-93 [21882284.001]
  • [Cites] Int J Geriatr Psychiatry. 2001 Sep;16(9):900-6 [11571771.001]
  • [Cites] Int Psychogeriatr. 2011 Dec;23(10):1616-22 [21902862.001]
  • [Cites] Int Psychogeriatr. 2006 Dec;18(4):713-26 [16879762.001]
  • [Cites] JAMA. 1994 Feb 2;271(5):358-62 [8283585.001]
  • [Cites] Eur J Clin Pharmacol. 2016 Aug;72 (8):987-94 [27071994.001]
  • [Cites] Alzheimers Dement. 2012 Sep;8(5):453-7 [22285636.001]
  • [Cites] Health Serv Res. 2009 Apr;44(2 Pt 1):379-98 [19178586.001]
  • [Cites] BMC Pharmacol Toxicol. 2013 Feb 08;14:10 [23391323.001]
  • [Cites] Arch Gen Psychiatry. 2011 Feb;68(2):190-7 [21300946.001]
  • [Cites] Acta Psychiatr Scand. 2015 Jul;132(1):20-8 [25532774.001]
  • [Cites] Am J Alzheimers Dis Other Demen. 2011 Feb;26(1):10-28 [21282274.001]
  • [Cites] Dement Geriatr Cogn Disord. 2013;35(5-6):239-48 [23485654.001]
  • [Cites] J Am Med Dir Assoc. 2014;15(11):812-8 [25129474.001]
  • [Cites] PLoS Med. 2008 Apr 1;5(4):e76 [18384230.001]
  • [Cites] Int Psychogeriatr. 2013 Sep;25(9):1415-23 [23782794.001]
  • [Cites] Int J Geriatr Psychiatry. 2014 Mar;29(3):263-71 [23846797.001]
  • [Cites] JAMA. 2005 Feb 2;293(5):596-608 [15687315.001]
  • (PMID = 28705243.001).
  • [ISSN] 1471-244X
  • [Journal-full-title] BMC psychiatry
  • [ISO-abbreviation] BMC Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Antipsychotic medication / Dementia / Directive / Drug utilization
  •  go-up   go-down


8. Xu G, Bai F, Lin X, Wang Q, Wu Q, Sun S, Jiang C, Liang Q, Gao B: Association between Antihypertensive Drug Use and the Incidence of Cognitive Decline and Dementia: A Meta-Analysis of Prospective Cohort Studies. Biomed Res Int; 2017;2017:4368474

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between Antihypertensive Drug Use and the Incidence of Cognitive Decline and Dementia: A Meta-Analysis of Prospective Cohort Studies.
  • Background: Antihypertensive drug use is inconsistently associated with the risk of dementia, Alzheimer's disease, cognitive impairment, and cognitive decline.
  • Only prospective cohort studies that reported effect estimates with corresponding 95% confidence intervals (CIs) of dementia, Alzheimer's disease, cognitive impairment, and cognitive decline for antihypertensive drug use versus not using antihypertensive drugs were included.
  • Overall, participants who received antihypertensive drugs had lower incidence of dementia (relative risk [RR]: 0.86; 95% CI: 0.75-0.99; <i>p</i> = 0.033), while there was no significant effect on the incidence of Alzheimer's disease (RR: 0.83; 95% CI: 0.64-1.09; <i>p</i> = 0.154), cognitive impairment (RR: 0.89; 95% CI: 0.57-1.38; <i>p</i> = 0.596), and cognitive decline (RR: 1.11; 95% CI: 0.86-1.43; <i>p</i> = 0.415).
  • Further, the incidence of Alzheimer's disease might be affected by antihypertensive drug use in participants with specific characteristics.
  • Conclusions: Antihypertensive drug use was associated with a significantly reduced risk of dementia, but not with the risk of Alzheimer's disease, cognitive impairment, and cognitive decline.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stroke. 2004 Aug;35(8):1810-5 [15232128.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3227-32 [9501245.001]
  • [Cites] Arch Neurol. 2010 May;67(5):564-9 [20457955.001]
  • [Cites] Stroke. 2002 Jan;33(1):26-30 [11779884.001]
  • [Cites] Circulation. 2011 Mar 15;123(10):1138-43 [21233236.001]
  • [Cites] Diabetologia. 2008 Feb;51(2):241-8 [18060658.001]
  • [Cites] Int J Clin Pract. 2011 Dec;65(12):1295-305 [22093537.001]
  • [Cites] Biometrics. 1994 Dec;50(4):1088-101 [7786990.001]
  • [Cites] Neurology. 2016 Aug 9;87(6):601-8 [27402894.001]
  • [Cites] Neurology. 2013 Sep 3;81(10 ):896-903 [23911756.001]
  • [Cites] J Am Coll Cardiol. 2011 May 17;57(20):2037-114 [21524875.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] Hypertension. 2009 Aug;54(2):233-40 [19564551.001]
  • [Cites] J Alzheimers Dis. 2008 May;13(4):421-35 [18487850.001]
  • [Cites] Stat Med. 2002 Jun 15;21(11):1559-73 [12111920.001]
  • [Cites] Age (Dordr). 2013 Apr;35(2):441-53 [22203459.001]
  • [Cites] Am J Hypertens. 2016 Feb;29(2):202-16 [26137952.001]
  • [Cites] BMJ. 2013 Jul 29;347:f4600 [23900315.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] Arch Neurol. 2006 May;63(5):686-92 [16533956.001]
  • [Cites] Neurology. 2006 May 9;66(9):1399-404 [16682673.001]
  • [Cites] J Am Geriatr Soc. 2013 Dec;61(12):2168-73 [24479146.001]
  • [Cites] Aging Cell. 2007 Jun;6(3):267-73 [17517038.001]
  • [Cites] Neurology. 2005 Aug 23;65(4):545-51 [16116114.001]
  • [Cites] Neurobiol Aging. 2001 May-Jun;22(3):407-12 [11378246.001]
  • [Cites] Med Decis Making. 2005 Nov-Dec;25(6):646-54 [16282215.001]
  • [Cites] BMJ. 1997 Sep 13;315(7109):629-34 [9310563.001]
  • [Cites] Arch Neurol. 2011 Sep;68(9):1185-90 [21555601.001]
  • [Cites] BMJ. 2009 Nov 24;339:b4567 [19934192.001]
  • [Cites] Atherosclerosis. 2014 Mar;233(1):19-26 [24529116.001]
  • [Cites] Blood Press. 2005;14(6):353-8 [16403689.001]
  • [Cites] J Neurosci. 1992 Feb;12(2):376-89 [1346802.001]
  • [Cites] PLoS Med. 2009 Jul 21;6(7):e1000097 [19621072.001]
  • (PMID = 29094046.001).
  • [ISSN] 2314-6141
  • [Journal-full-title] BioMed research international
  • [ISO-abbreviation] Biomed Res Int
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


9. Yang JS, Wu XH, Yu HG, Teng LS: Tangeretin inhibits neurodegeneration and attenuates inflammatory responses and behavioural deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease dementia in rats. Inflammopharmacology; 2017 Aug;25(4):471-484
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tangeretin inhibits neurodegeneration and attenuates inflammatory responses and behavioural deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease dementia in rats.
  • Our aim was to investigate whether tangeretin, a citrus flavonoid, was able to prevent neuroinflammation and improve dementia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced rodent model of Parkinson's disease (PD).
  • The experimental data suggest tangeretin as an effective candidate drug with potential for prevention and treatment of neuroinflammation and dementia associated with PD.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Behav Brain Res. 2011 Jun 1;219(2):280-90 [21262271.001]
  • [Cites] Neurotox Res. 2016 Feb;29(2):275-87 [26607911.001]
  • [Cites] Neurosci Lett. 2000 Jun 23;287(2):117-20 [10854726.001]
  • [Cites] Behav Brain Res. 2008 Apr 9;188(2):310-5 [18178264.001]
  • [Cites] J Neurosci Methods. 2005 Oct 15;148(1):78-87 [15939479.001]
  • [Cites] Behav Brain Res. 1988 Nov 1;31(1):47-59 [3228475.001]
  • [Cites] Eur J Neurosci. 2001 Feb;13(3):529-38 [11168560.001]
  • [Cites] J Agric Food Chem. 2008 Aug 13;56(15):6185-205 [18593176.001]
  • [Cites] Clin Neurosci Res. 2006 Dec 6;6(5):261-281 [18060039.001]
  • [Cites] Neuroscience. 2004;127(2):289-300 [15262320.001]
  • [Cites] J Neurol. 2000 Apr;247 Suppl 2:II25-35 [10991662.001]
  • [Cites] Glia. 2005 Nov 1;52(2):144-52 [15920722.001]
  • [Cites] Trends Mol Med. 2013 Mar;19(3):187-96 [23318001.001]
  • [Cites] Acta Anaesthesiol Scand. 2013 Mar;57(3):380-90 [23186353.001]
  • [Cites] Front Biosci. 2003 Sep 01;8:s992-7 [12957858.001]
  • [Cites] Behav Brain Res. 2014 Jul 15;268:177-84 [24755306.001]
  • [Cites] Eur J Neurosci. 2003 Sep;18(5):1175-88 [12956716.001]
  • [Cites] Neurobiol Aging. 2012 Aug;33(8):1777-91 [21524431.001]
  • [Cites] Neurosci Lett. 1998 Jun 26;250(1):25-8 [9696057.001]
  • [Cites] Neuropsychologia. 2003;41(5):565-74 [12559149.001]
  • [Cites] J Neurosci. 2005 Mar 2;25(9):2322-9 [15745958.001]
  • [Cites] Behav Brain Res. 2001 Sep 28;124(1):9-18 [11423161.001]
  • [Cites] FASEB J. 2003 Mar;17 (3):500-2 [12631585.001]
  • [Cites] Eur J Pharmacol. 2003 Dec 15;482(1-3):215-22 [14660025.001]
  • [Cites] Neuroscience. 1999 Jan;88(1):1-16 [10051185.001]
  • [Cites] Exp Neurol. 2005 Oct;195(2):322-9 [16005872.001]
  • [Cites] Lancet Neurol. 2003 Apr;2(4):229-37 [12849211.001]
  • [Cites] Parkinsonism Relat Disord. 2004 May;10 Suppl 1:S3-7 [15109580.001]
  • [Cites] Mediators Inflamm. 2013;2013:952375 [23935251.001]
  • [Cites] FASEB J. 2006 Apr;20(6):670-82 [16581975.001]
  • [Cites] Restor Neurol Neurosci. 2013;31(1):87-97 [23047495.001]
  • [Cites] J Neuroimmunol. 2008 Nov 15;204(1-2):43-51 [18817984.001]
  • [Cites] Food Chem Toxicol. 2014 Sep;71:176-82 [24955543.001]
  • [Cites] Cancer Chemother Pharmacol. 2015 Feb;75(2):263-72 [25431347.001]
  • [Cites] Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S210-2 [22166438.001]
  • [Cites] J Food Sci. 2016 May;81(5):H1320-7 [27095513.001]
  • [Cites] Neuroimage. 2006 Oct 15;33(1):374-82 [16904344.001]
  • [Cites] Behav Neurosci. 1988 Oct;102(5):748-59 [2904271.001]
  • [Cites] Acta Neuropathol. 2003 Dec;106(6):518-26 [14513261.001]
  • [Cites] Behav Brain Res. 2012 Apr 1;229(1):41-7 [22227506.001]
  • [Cites] Neurobiol Learn Mem. 2008 Feb;89(2):192-8 [17702614.001]
  • [Cites] Brain Res Bull. 2001 May 1;55(1):101-6 [11427344.001]
  • [Cites] J Neurosci. 2004 May 12;24(19):4596-604 [15140931.001]
  • [Cites] Hippocampus. 2005;15(8):1050-6 [16145694.001]
  • [Cites] J Neurosci Res. 1999 May 15;56(4):441-6 [10340751.001]
  • [Cites] Behav Brain Res. 2006 Apr 25;169(1):142-9 [16455144.001]
  • [Cites] Curr Alzheimer Res. 2005 Jul;2(3):355-65 [15974901.001]
  • [Cites] Neurobiol Learn Mem. 2008 May;89(4):522-32 [18304843.001]
  • [Cites] Neuroscience. 2005;133(3):831-40 [15893432.001]
  • [Cites] Prog Neurobiol. 2000 Sep;62(1):63-88 [10821982.001]
  • [Cites] Immunopharmacology. 1998 Jun;39(3):167-80 [9754903.001]
  • [Cites] Neuropharmacology. 2008 Mar;54(3):620-7 [18164319.001]
  • [Cites] Neuroreport. 2001 Dec 4;12(17):3871-5 [11726811.001]
  • [Cites] J Neurosci. 2000 Aug 1;20(15):5715-23 [10908611.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1988 Dec;51(12):1498-502 [3221216.001]
  • [Cites] Behav Brain Res. 2010 Mar 17;208(1):38-46 [19900486.001]
  • [Cites] Neurosci Res. 2006 Sep;56(1):96-102 [16846658.001]
  • [Cites] Neurology. 2005 Apr 26;64(8):1404-10 [15851731.001]
  • [Cites] Exp Neurol. 2005 Mar;192(1):134-41 [15698627.001]
  • [Cites] Brain Res. 2000 Mar 31;860(1-2):190-4 [10727642.001]
  • [Cites] Biomed Pharmacother. 2016 Jul;81:491-6 [27261630.001]
  • [Cites] Neuropharmacology. 2015 Apr;91:43-56 [25499022.001]
  • [Cites] Nat Neurosci. 2001 Jul;4(7):702-10 [11426226.001]
  • [Cites] J Neural Transm Suppl. 2000;(58):143-51 [11128604.001]
  • [Cites] Am J Psychiatry. 1995 Sep;152(9):1291-7 [7653683.001]
  • [Cites] Ann Neurol. 1999 Oct;46(4):598-605 [10514096.001]
  • [Cites] Dev Neurosci. 1998;20(1):1-18 [9600386.001]
  • [Cites] Neurobiol Dis. 2008 Nov;32(2):319-27 [18718537.001]
  • [Cites] Nat Rev Neurol. 2010 Apr;6(4):193-201 [20234358.001]
  • [Cites] J Am Assoc Lab Anim Sci. 2011 Jan;50(1):41-5 [21333162.001]
  • [Cites] Behav Neurosci. 2009 Dec;123(6):1261-70 [20001109.001]
  • [Cites] Pharmacol Biochem Behav. 2010 Apr;95(2):158-65 [20064549.001]
  • [Cites] Eur J Pharmacol. 2008 Oct 10;594(1-3):101-8 [18674531.001]
  • [Cites] Phytother Res. 2013 Apr;27(4):564-71 [22678994.001]
  • [Cites] Parkinsonism Relat Disord. 2005 Jun;11 Suppl 1:S9-S15 [15885630.001]
  • [Cites] Br J Pharmacol. 2007 Apr;150(8):963-76 [17339843.001]
  • [Cites] Acta Neuropathol. 2005 Feb;109(2):141-50 [15619128.001]
  • [Cites] Mol Genet Metab. 1998 Feb;63(2):142-7 [9562968.001]
  • [Cites] Glia. 2004 May;46(4):402-9 [15095370.001]
  • [Cites] Neurotoxicology. 2012 Mar;33(2):147-55 [22281204.001]
  • [Cites] Neurosci Lett. 2003 May 1;341(2):87-90 [12686372.001]
  • [Cites] Mov Disord. 2006 Sep;21(9):1483-7 [16705661.001]
  • [Cites] Pharmacol Biochem Behav. 2012 Jul;102(1):64-71 [22487770.001]
  • [Cites] J Neuroimmune Pharmacol. 2016 Jun;11(2):294-305 [26899309.001]
  • (PMID = 28577132.001).
  • [ISSN] 1568-5608
  • [Journal-full-title] Inflammopharmacology
  • [ISO-abbreviation] Inflammopharmacology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) / Dementia / Inflammatory cytokines / Neurodegeneration / Parkinson’s disease / Tangeretin
  •  go-up   go-down


10. Allers K, Dörks M, Schmiemann G, Hoffmann F: Antipsychotic drug use in nursing home residents with and without dementia: keep an eye on the pro re nata medication. Int Clin Psychopharmacol; 2017 Jul;32(4):213-218

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antipsychotic drug use in nursing home residents with and without dementia: keep an eye on the pro re nata medication.
  • Behavioral and psychological symptoms of dementia often lead to the prescription of antipsychotics, especially in nursing homes, but their use remains controversial.
  • This study aimed to assess antipsychotic drug use in residents with dementia compared with those without dementia.
  • Overall, 57.5% of the 837 residents had a diagnosis of dementia and 47.0% of residents with dementia and 19.5% of those without dementia received antipsychotics.
  • 35.9% of all antipsychotics in residents with dementia were prescribed as pro re nata (PRN) compared with 23.0% for residents without dementia.
  • The adjusted logistic regression showed a significant association between the prescription of antipsychotics and dementia (odds ratio: 3.58, 95% confidence interval: 2.45-5.25) as well as severe care dependency (odds ratio: 1.68, 95% confidence interval: 1.10-2.55).
  • Despite safety warnings, antipsychotics are still frequently prescribed to residents with dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28346296.001).
  • [ISSN] 1473-5857
  • [Journal-full-title] International clinical psychopharmacology
  • [ISO-abbreviation] Int Clin Psychopharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement